Zhong-yin Yang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Intraperitoneal and intravenous paclitaxel plus S-1 and sintilimab as first-line treatment for gastric cancer with peritoneal metastasis: a single-arm phase 2 trial (DRAGON-09).
Journal: EClinicalMedicine
Published: August 13, 2025
Perioperative systemic and prophylactic intraperitoneal chemotherapy for type 4/large type 3 gastric cancer: DRAGON-10.
Journal: Future oncology (London, England)
Published: October 08, 2024
A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial.
Journal: Future oncology (London, England)
Published: January 18, 2023
Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: October 16, 2022
Efficacy and Safety of Conversion Therapy by Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis: A Prospective Phase II Study.
Journal: Frontiers in oncology
Published: March 28, 2022
A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Journal: Future oncology (London, England)
Published: February 04, 2022
A randomized controlled trial to evaluate omentum-preserving gastrectomy for patients with T1-T3 gastric cancer.
Journal: Future oncology (London, England)
Published: May 19, 2021
Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery.
Journal: Oncology letters
Published: August 28, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026